How Much Did Resverlogix Raise?
Funding & Key Investors

Resverlogix, a prominent player in the late-stage clinical biotechnology sector, has successfully secured a total funding amount of $264M to advance its pipeline of novel therapeutics. This capital trajectory, bolstered by a recent funding amount of $6M, underscores the market confidence in the company's proprietary research and development efforts. By consistently attracting institutional backing, Resverlogix has maintained the necessary liquidity to navigate the rigorous demands of late-stage clinical development and regulatory milestones.

The company's history of financing reflects a deliberate strategy to support its core asset, apabetalone, through complex Phase III clinical trials. This sustained investment flow highlights the high-stakes nature of developing small molecule selective bromodomain and extra-terminal inhibitors, positioning the firm as a critical entity in the pursuit of treatments for cardiovascular, renal, and neurodegenerative conditions.